Strategies to Reduce Morbidity and Mortality in COPD: A Patient-focused Approach for Integration of Combination and Triple Therapy – Tweetorial #2




This CME activity is provided by Integrity Continuing Education, Inc.
This CE activity for ANCC and ACPE credit is jointly provided by Global Education Group and Integrity Continuing Education, Inc.

This program is being implemented in collaboration with the COPD Foundation.


This activity is supported by an educational grant from AstraZeneca Pharmaceuticals.


Treatable Traits Approach


Chronic obstructive pulmonary disorder (COPD) is a complex and heterogeneous disease that is associated with significant morbidity and mortality. Despite efforts to standardize the diagnosis, treatment, and management of this progressive disease, many patients receive a delayed diagnosis or remain undiagnosed and face dismal outcomes. Several pharmacologic therapies and continually updated guideline recommendations are available, however, COPD is suboptimally treated in current clinical practice. As a result, patients with COPD are associated with a poor quality of life, with many patients living in discomfort and experiencing debilitating exacerbations. Recently, evidence has demonstrated the utility of dual and triple therapy combinations of agents in reducing exacerbations among patients with COPD and updated guidelines have identified specific patient subsets that can benefit from these approaches. This educational initiative will inform participants regarding the utility of recently published evidence, precision medicine-based approaches, and updated GOLD and ATS guidelines to address underdiagnosis and suboptimal treatment of COPD and allow healthcare providers to overcome existing barriers to achieve improved outcomes among patients with COPD.

This is a Twitter-based tutorial designed to provide key information in an accessible format and location.


Fernando J. Martinez, MD, MS
Chief, Pulmonary and Critical Care Medicine
Bruce Webster Professor of Medicine
Joan and Sanford I. Weill Department of Medicine
Weill Cornell Medical College
New York-Presbyterian Hospital/Weill Cornell Medical Center
New York, New York


Surya P. Bhatt, MD
Associate Professor of Medicine
Department of Pulmonary, Allergy and Critical Care Medicine
University of Alabama at Birmingham
Birmingham, Alabama


Release date: June 24, 2021
Expiration date: June 24, 2022
Estimated time to complete activity: 0.25 hour



This program is intended for pulmonologists, respiratory therapists, and internal medicine physicians involved in the management of patients with COPD and for acute care clinicians involved in the management of patients with COPD exacerbations.


Upon completion of this educational activity, participants should be able to:

  • Review updated guidelines and recommendations for the use of combination bronchodilator therapy to optimize treatment and management of COPD

There are no fees for participating and receiving CME credit for this activity. During the period of June 24, 2021 through June 24, 2022, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 100%. For Pharmacist/ACPE learners, please check CPE monitor for your credit within 60 days of the activity.




Physician Continuing Medical Education Accreditation Statement

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physician Continuing Medical Education Credit Designation
Integrity Continuing Education, Inc. designates this other activity for a maximum of0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

This educational activity for 0.25 contact hour is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.


Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.


Global Education Group designates this continuing education activity for 0.25 contact hour(s) (0.025 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number 0530-9999-21-056-H01-P)

This is a knowledge-based activity.


For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or

For information about ACPE or ANCC accreditation of this activity, please contact Global at (303) 395-1782 or


Integrity Continuing Education, Inc. and Global Education Group (Global) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of these CME activities:

Fernando J. Martinez, MD, MS
Consulting Fees: AbbVie, AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, CSL Behring,  DevPro, GlaxoSmithKline, IQVIA, Novartis, Polarean, Proterrix Bio, Raziel, Sanofi/Regeneron, Shionogi, Teva, United Therapeutics, Veracyte, Verona
Study Steering Committee: Afferent/Merck, AstraZeneca, Bayer, Boehringer Ingelheim, Biogen, Gilead, GlaxoSmithKline, Patara/Respivant, ProMedior/Roche, Sanofi/Regeneron, Veracyte
DSMB: Biogen, Boehringer Ingelheim, GlaxoSmithKline, Medtronic

Surya P. Bhatt, MD
Consulting Fees: Boehringer Ingelheim, Sanofi

The Global Education Group planners and managers have the following relevant financial relationships with ineligible companies: Ashley Marostica, RN, MSN, Lindsay Borvansky, Andrea Funk, Liddy Knight, and Ashley Cann have nothing to disclose.

The Integrity Continuing Education, Inc. planners and managers have nothing to disclose.

The COPD Foundation planners and managers having the following relevant financial relationships with ineligible companies to disclose:

Michael W. Hess
Consultant: Boehringer Ingelheim
Speaker: Boehringer Ingelheim, Olympus, Theravance Biopharma, Vitalograph
Advisory Board: Theravance Biopharma

Ruth Tal-Singer, PhD
Consultant: ENA Respiratory, ImmunoMet, Teva, VOCALIS Health
Board of Directors (unpaid): ENA Respiratory
Shareholder: GSK
Other: GSK – Retiree (October 2019)

Kristen Willard has no real or apparent conflicts of interest to disclose.


This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)


Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe® Flash® Player 10

  • Adobe® Flash® Player 10 plug-in should be downloaded
  • Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements


The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Continue to Pretest